ABT-494
Sponsors
AbbVie (prior sponsor, Abbott), AbbVie, AbbVie Deutschland GmbH & Co. KG
Conditions
Crohn syndrome
regional enteritisCrohn's DiseaseCrohn's Disease (CD)Rheumatoid Arthritis
Phase 1
Phase 2
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
CompletedNCT01960855
Start: 2013-10-31End: 2015-07-31Updated: 2021-08-24
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
CompletedNCT02365649
Start: 2015-03-17End: 2017-08-03Updated: 2023-12-27
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
CompletedNCT02782663
Start: 2016-05-18End: 2025-07-18Updated: 2025-07-31
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Immunomodulators or Anti-TNF Therapy
Active, not recruitingNL-OMON44996
Start: 2016-01-06Target: 22Updated: 2024-02-28